Interferon Beta-1a
Performance & EnduranceInterferon for multiple sclerosis, modulates immune system to reduce relapses.
Key Benefits
- ✓Reduces MS relapses
- ✓Slows disability progression
- ✓Immune modulation
- ✓Multiple dosing options
- ✓Established MS therapy
Dosing Information
Detailed Protocol
Administered via intramuscular injection weekly (Avonex) or subcutaneous 3x weekly (Rebif). Premedication with acetaminophen/ibuprofen reduces flu-like symptoms. Prescription only.
About Interferon Beta-1a
Interferon beta-1a (Avonex, Rebif) is a cytokine that modulates immune responses. FDA-approved for relapsing forms of multiple sclerosis to reduce frequency of relapses. Available in weekly (Avonex) or 3x weekly (Rebif) formulations.
Research Notes
FDA-approved for MS since 1996 (Avonex). Long-established MS therapy. Newer agents (anti-CD20s, etc.) often preferred now but still viable option. Requires regular monitoring.
Potential Side Effects
- •Flu-like symptoms very common
- •Injection site reactions
- •Depression
- •Liver enzyme elevations
- •Cytopenias
- •Requires monitoring
Always consult with a healthcare professional before starting any peptide therapy.